Lipocine Inc. Logo Image

Lipocine Inc.

Most Recent Annual Report

2017 Annual Report and Form 10K

Lipocine Inc.

Lipocine Inc. has reached its limit for free report views.

Lipocine Inc. does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Archived Annual Reports

About Lipocine Inc.

11-50 Employees
Based in Salt Lake City, Utah

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes three development programs LPCN 1021, LPCN 1111 and LPCN 1107. LPCN 1021, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men.

Ticker:
LPCN
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Drugs - Generic (See More Drugs - Generic Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol